This inventor holds 1 USPTO granted patent. Top assignees: Johns Hopkins University, Leland Stanford Junior University. Active years: 2011.
Company Filing History:
1 out of 3,795 
1 out of 5,497 
Years Active: 2011
Title: Jynho Kim: Innovator in Hematopoietic Malignancy Treatment
Introduction
Jynho Kim is a notable inventor based in Palo Alto, CA, who has made significant contributions to the field of medical research. His work primarily focuses on the treatment of hematopoietic malignancies through innovative methods targeting the Hedgehog (Hh) signaling pathway. With a patent portfolio that includes groundbreaking research, Kim is recognized for his efforts in advancing cancer treatment.
Latest Patents
Jynho Kim holds a patent for "Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies." This patent addresses the elevated Hedgehog pathway activity found in hematopoietic malignancy cells, which is associated with their growth and proliferation. The methods outlined in the patent provide strategies for treating hematopoietic cell malignancies by reducing or inhibiting Hh pathway activity. Additionally, the patent includes methods for determining the responsiveness of these malignancies to treatment with Hh pathway antagonists. Kim's innovative approach has the potential to improve therapeutic outcomes for patients suffering from these conditions.
Career Highlights
Throughout his career, Jynho Kim has worked with prestigious institutions, including Johns Hopkins University and Leland Stanford Junior University. His research has contributed to a deeper understanding of the mechanisms underlying hematopoietic malignancies and has paved the way for new treatment options. His dedication to advancing medical science is evident in his focused research efforts and innovative solutions.
Collaborations
Jynho Kim has collaborated with notable figures in the field, including Philip Arden Beachy. These partnerships have enhanced the scope and impact of his research, fostering an environment of innovation and discovery.
Conclusion
Jynho Kim's contributions to the field of hematopoietic malignancy treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work continues to inspire advancements in medical research and treatment methodologies.